Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2006 Feb;44(2):318-23.
doi: 10.1128/JCM.44.2.318-323.2006.

Evaluation of the invader assay for genotyping hepatitis C virus

Jeffrey J Germer  1 , David W Majewski, Billy Yung, P Shawn Mitchell, Joseph D C Yao
Affiliations

Evaluation of the invader assay for genotyping hepatitis C virus

Jeffrey J Germer et al. J Clin Microbiol. 2006 Feb.

Abstract

The Invader 1.0 assay (Invader HCV Genotyping Assay, version 1.0; Third Wave Technologies, Inc., Madison, WI) has been developed for the rapid differentiation of hepatitis C virus (HCV) genotypes 1 to 6 based on sequence variation within the HCV 5' noncoding (NC) region. In the present study, we evaluated the compatibility of Invader 1.0 with the COBAS MONITOR (COBAS AMPLICOR HCV MONITOR Test, version 2.0; Roche Molecular Systems, Inc., Branchburg, NJ), COBAS AMPLICOR (COBAS AMPLICOR Hepatitis C Virus Test, version 2.0; Roche Molecular Systems, Inc.), and COBAS TaqMan (COBAS TaqMan HCV Test; Roche Molecular Systems, Inc.) assays. The minimum HCV RNA titers required for successful HCV genotyping (>/=90% success rate) were 1,000 IU/ml for COBAS MONITOR, 100 IU/ml for COBAS AMPLICOR, and 10 IU/ml for COBAS TaqMan. Invader 1.0 results obtained from unpurified COBAS TaqMan amplification products of 111 retrospectively selected clinical serum specimens (genotypes 1 to 6, with virus titers ranging from 15.1 to 2.1 x 10(7) IU/ml) showed 98% concordance with results obtained from the TRUGENE HCV 5' NC Genotyping Kit (Bayer HealthCare LLC, Tarrytown, NY), used in conjunction with COBAS AMPLICOR. Although the assay is sensitive, accurate, and easy to perform, additional optimization of the Invader 1.0 interpretive software (Invader Data Analysis Worksheet) may be necessary to reduce potential misidentification of HCV genotypes in low-titer specimens. In summary, Invader 1.0 is compatible with a variety of commercially available PCR-based HCV 5' NC region amplification assays and is suitable for routine HCV genotyping in clinical laboratories.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
Principles of Invader 1.0.
See this image and copyright information in PMC

References

    1. Armstrong, G. L., M. J. Alter, G. M. McQuillan, and H. S. Margolis. 2000. The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology 31:777-782. - PubMed
    1. European Association for the Study of the Liver. 1999. Consensus statement. J. Hepatol. 30:956-961. - PubMed
    1. Germer, J. J., W. S. Harmsen, J. N. Mandrekar, P. S. Mitchell, and J. D. C. Yao. 2005. Evaluation of the COBAS TaqMan HCV Test with automated sample processing using the MagNA Pure LC instrument. J. Clin. Microbiol. 43:293-298. - PMC - PubMed
    1. Holland, J., I. Bastian, R. M. Ratcliff, M. Y. Beers, P. Hahesy, H. Harley, D. R. Shaw, and G. D. Higgins. 1998. Hepatitis C genotyping by direct sequencing of the product from the Roche AMPLICOR test: methodology and application to a South Australian population. Pathology 30:192-195. - PubMed
    1. Ledford, M., K. D. Friedman, M. J. Hessner, C. Moehlenkamp, T. M. Williams, and R. S. Larson. 2000. A multisite study for detection of the factor V (Leiden) mutation from genomic DNA using a homogeneous Invader microtiter plate fluorescence resonance energy transfer (FRET) assay. J. Mol. Diagn. 2:97-104. - PMC - PubMed

Publication types